Moderna shares advanced markedly after positive results from a skin cancer trial conducted with Merck. The stock jumped nearly 100 percent, with reports detailing surges of over 150 percent and increases between 85 and 90 percent. The trial concentrated on an mRNA melanoma vaccine created together by Moderna and Merck.
The promising trial results indicated advances for mRNA cancer treatments. Financial Times reported that Moderna shares soared over 150 percent in the wake of the skin cancer drug trial success. Yahoo Finance UK indicated shares rose sharply 85 percent toward their best day ever. The Australian said that drug giants Moderna and Merck disclosed positive outcomes for the new melanoma vaccine.